NASA’s Johnson Space Center in Houston and Epiomed Therapeutics Inc. of Irvine, Calif., have signed an agreement to develop a fast-acting nasal spray to fight Motion Sickness.
Under the Space Act Agreement, Epiomed will formulate the drug, called intranasal scopolamine, or INSCOP. Astronauts often experience motion sickness in space. As a result, NASA has conducted extensive research into the causes and treatments for the condition. Scopolamine is effective and can be administered as a tablet or injected. With a precise dosage, the NASA spray formulation has been shown to work faster and more reliably than the oral form.
“NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas,” said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson.
[This article was found on ScienceDaily.com. You may read the rest of the article here – http://www.sciencedaily.com/releases/2012/10/121012152519.htm]